Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | SEE REMARKS | June 14, 2024 | June 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date June 14, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,022 |
Reported balance
After 2024-06-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-14 · Exercise / conversion · Acquired 15,000 · Balance 20,022 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F2: Includes 3,062 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d). |
| Common StockSEC Table I · non-derivative | Direct | 5,022 |
Reported balance
After 2024-06-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-06-14 · Sale · Disposed 15,000 · Balance 5,022 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01 | Direct | 28,763 |
Reported balance
After 2024-06-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-14 · Exercise / conversion · Disposed 15,000 · Balance 28,763 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F3: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
F2: Includes 3,062 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d).
F3: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2024 Filed Jun 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-016995 · form4-06142024_060606.xml · derivative · entry 3 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,763 Underlying: Common Stock · 15,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F3 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 15,000 | $25.03 | $375,450.00 |
DisclosureSEC source: 0001415889-24-016995 · form4-06142024_060606.xml · nonDerivative · entry 2 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,022 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 15,000 | $2.14 | $32,100.00 |
DisclosureSEC source: 0001415889-24-016995 · form4-06142024_060606.xml · nonDerivative · entry 1 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F2 · balance_after: Includes 3,062 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d). Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-010773 · form4-04122024_060401.xml · derivative · entry 4 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,763 Underlying: Common Stock · 7,500 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F4 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 771 | $27.56 | $21,252.31 |
DisclosureSEC source: 0001415889-24-010773 · form4-04122024_060401.xml · nonDerivative · entry 3 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.35 to $27.74, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 6,729 | $26.77 | $180,139.37 |
DisclosureSEC source: 0001415889-24-010773 · form4-04122024_060401.xml · nonDerivative · entry 2 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,731 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.32 to $27.315, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 7,500 | $2.14 | $16,050.00 |
DisclosureSEC source: 0001415889-24-010773 · form4-04122024_060401.xml · nonDerivative · entry 1 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,495 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-010136 · form4-04032024_060404.xml · derivative · entry 3 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,768 Underlying: Common Stock · 12,495 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F3 · derivative.exercise_date: A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 12,495 | $31.23 | $390,207.60 |
DisclosureSEC source: 0001415889-24-010136 · form4-04032024_060404.xml · nonDerivative · entry 2 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 12,495 | $2.14 | $26,739.30 |
DisclosureSEC source: 0001415889-24-010136 · form4-04032024_060404.xml · nonDerivative · entry 1 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. Read SEC document |
| March 13, 2024 Filed Mar 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,016 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-008033 · form4-03142024_060304.xml · derivative · entry 6 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,263 Underlying: Common Stock · 2,016 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F4 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 13, 2024 Filed Mar 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,016 | $25.02 | $50,444.96 |
DisclosureSEC source: 0001415889-24-008033 · form4-03142024_060304.xml · nonDerivative · entry 4 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.08, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 13, 2024 Filed Mar 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,016 | $2.14 | $4,314.24 |
DisclosureSEC source: 0001415889-24-008033 · form4-03142024_060304.xml · nonDerivative · entry 3 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,051 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-008033 · form4-03142024_060304.xml · derivative · entry 5 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,279 Underlying: Common Stock · 2,051 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F4 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,051 | $25.05 | $51,369.55 |
DisclosureSEC source: 0001415889-24-008033 · form4-03142024_060304.xml · nonDerivative · entry 2 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.19, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,051 | $2.14 | $4,389.14 |
DisclosureSEC source: 0001415889-24-008033 · form4-03142024_060304.xml · nonDerivative · entry 1 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,433 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-007534 · form4-03112024_060307.xml · derivative · entry 11 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,330 Underlying: Common Stock · 3,433 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F5 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 10 | $26.31 | $263.05 |
DisclosureSEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 7 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,423 | $25.24 | $86,404.39 |
DisclosureSEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 6 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,970 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 3,433 | $2.14 | $7,346.62 |
DisclosureSEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 5 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,393 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 114 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-007534 · form4-03112024_060307.xml · derivative · entry 10 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,763 Underlying: Common Stock · 114 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F5 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 114 | $25.00 | $2,850.00 |
DisclosureSEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 4 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 114 | $2.14 | $243.96 |
DisclosureSEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 3 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,986 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-007534 · form4-03112024_060307.xml · derivative · entry 9 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,877 Underlying: Common Stock · 20,986 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F5 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,400 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-007534 · form4-03112024_060307.xml · derivative · entry 8 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,263 Underlying: Common Stock · 1,400 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F4 · derivative.exercise_date: A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 22,386 | $25.00 | $559,688.06 |
DisclosureSEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 2 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.289, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 22,386 | $2.14 | $47,906.04 |
DisclosureSEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 1 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Options (Right to Buy) · Derivative | 66,586 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001772 · form4-01242024_060102.xml · derivative · entry 1 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,586 Underlying: Common Stock · 66,586 shares Expires 2034-01-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 23:10 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $25.57 | $0.00 |
DisclosureSEC source: 0001415889-23-002173 · form4-02082023_060206.xml · derivative · entry 1 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-02-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on March 7, 2023. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,906 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012508 · form4-12132022_061201.xml · derivative · entry 8 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,863 Underlying: Common Stock · 2,906 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F6 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,094 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012508 · form4-12132022_061201.xml · derivative · entry 7 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,663 Underlying: Common Stock · 7,094 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F5 · derivative.exercise_date: A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 10,000 | $30.04 | $300,428.00 |
DisclosureSEC source: 0001415889-22-012508 · form4-12132022_061201.xml · nonDerivative · entry 5 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.39, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 10,000 | $2.14 | $21,400.00 |
DisclosureSEC source: 0001415889-22-012508 · form4-12132022_061201.xml · nonDerivative · entry 4 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,969 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012508 · form4-12132022_061201.xml · derivative · entry 6 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,757 Underlying: Common Stock · 3,969 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F5 · derivative.exercise_date: A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 583 | $25.23 | $14,710.66 |
DisclosureSEC source: 0001415889-22-012508 · form4-12132022_061201.xml · nonDerivative · entry 3 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.01 to $25.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,386 | $24.23 | $82,054.63 |
DisclosureSEC source: 0001415889-22-012508 · form4-12132022_061201.xml · nonDerivative · entry 2 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,543 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $25.00, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 3,969 | $2.14 | $8,493.66 |
DisclosureSEC source: 0001415889-22-012508 · form4-12132022_061201.xml · nonDerivative · entry 1 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,124 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012355 · form4-12092022_061201.xml · derivative · entry 10 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,726 Underlying: Common Stock · 10,124 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F7 · derivative.exercise_date: A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,887 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012355 · form4-12092022_061201.xml · derivative · entry 9 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,769 Underlying: Common Stock · 1,887 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F6 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 11,031 | $24.20 | $266,974.47 |
DisclosureSEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 7 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 20 | $20.58 | $411.60 |
DisclosureSEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 6 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,991 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 960 | $20.12 | $19,313.76 |
DisclosureSEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 5 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,011 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.575 to $20.54, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 12,011 | $2.14 | $25,703.54 |
DisclosureSEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 4 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,637 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012355 · form4-12092022_061201.xml · derivative · entry 8 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,656 Underlying: Common Stock · 11,637 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F6 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,558 | $20.40 | $92,992.77 |
DisclosureSEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 3 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.02 to $20.56, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 7,079 | $19.37 | $137,089.79 |
DisclosureSEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 2 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,518 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.97, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 11,637 | $2.14 | $24,903.18 |
DisclosureSEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 1 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. Read SEC document |
| November 30, 2022 Filed Dec 3, 2022 00:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 85 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-011982 · form4-12022022_071201.xml · derivative · entry 3 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,293 Underlying: Common Stock · 85 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F3 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 1, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 30, 2022 Filed Dec 3, 2022 00:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 85 | $19.06 | $1,620.13 |
DisclosureSEC source: 0001415889-22-011982 · form4-12022022_071201.xml · nonDerivative · entry 2 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 30, 2022 Filed Dec 3, 2022 00:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 85 | $2.14 | $181.90 |
DisclosureSEC source: 0001415889-22-011982 · form4-12022022_071201.xml · nonDerivative · entry 1 Eldridge George A · CIK 0001413006 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.